October 2026 hepatology news includes FDA approval of bepirovirsen for hepatitis B, new ACLF criteria, ACG cirrhosis guidance, and MASH trial data.
News|Articles|March 3, 2025
Hepatology Month in Review: February 2025
Author(s)Abigail Brooks, MA
The hepatology month in review spotlights HCPLive’s coverage of hepatic drug development and research about GLP-1 RAs, viral hepatitis, and MASH.
Advertisement
Advertisement
Building on a fast-paced start to 2025, February delivered another month of meaningful progress in
Related to this article
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
Five liver societies define ACLF as liver failure plus extrahepatic organ dysfunction or failure, with three grades and FDA-informed trial endpoints.
HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.
October 2026 allergy news: FDA approvals for berotralstat pellets and remibrutinib, RAPIDe-3 data in HAE, alpha-gal syndrome, and Viaskin Peanut Patch.
Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.
Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.
Advertisement
Advertisement